Rul­ing in SCO­TUS mifepri­s­tone case could lead to end­less lit­i­ga­tion, in­dus­try says

Last year
Pharma
FDA+

Apoc­a­lypse or rip­ple? Ahead of first of­fers on price, new re­search pre­dicts IRA im­pact on R&D will be mod­est

Last year
R&D
FDA+

Celebri­ty en­dorse­ments lift Idor­sia, Pfiz­er and No­var­tis TV ads to most ef­fec­tive for phar­ma in 2023, analy­sis finds

Last year
Pharma
Marketing

No­vavax an­nounces an­oth­er round of lay­offs, lets go 12% of em­ploy­ees

Last year
People
Coronavirus

In­sur­ers warn about ris­ing med­ical costs, dis­ap­point­ing in­vestors as a lu­cra­tive mar­ket starts to shift

Last year
Health Tech

Te­va plans sale of API unit amid 'piv­ot to growth'

Last year
Pharma
Manufacturing

Ther­mo Fish­er’s Q4 rev­enue dips due to ‘still mut­ed’ mar­ket

Last year
Pharma
Manufacturing

CMS de­tails pro­gram to use out­comes-based agree­ments to pay for sick­le cell gene ther­a­pies

Last year
Cell/Gene Tx

Hali­a's $30M Se­ries C; Windtree as­sess­es 's­trate­gic' op­tions; LifeArc, Gates in­vest in Africa ac­cel­er­a­tor

Last year
News Briefing

Vax­cyte prices $750M of­fer­ing, one of biotech’s largest, as it goes up against Big Phar­ma's pneu­mo­coc­cal vac­cines

Last year
Financing

Bio­gen to halt sales and de­vel­op­ment of con­tro­ver­sial Alzheimer's drug Aduhelm

Last year
R&D
Pharma

No­vo Nordisk con­tin­ues di­a­betes, obe­si­ty sales rise, but still on the back foot with We­govy sup­ply

Last year
Pharma
Manufacturing

Up­dat­ed: GSK takes vic­to­ry lap with block­buster sales for RSV vac­cine

Last year
Pharma

Up­dat­ed: No­var­tis ax­es blood can­cer drug af­ter PhI­II flop, cau­tions on obe­si­ty FO­MO

Last year
R&D
Pharma

FDA Com­mis­sion­er Robert Califf high­lights need for ‘cre­ative ap­proach­es’ for rare dis­ease ther­a­pies

Last year
FDA+

Ver­tex's next chal­lenge for pain pill? Crack­ing a mar­ket dom­i­nat­ed by cheap opi­oids

Last year
Pharma

DOJ dis­miss­es in­sid­er trad­ing charges against Vi­a­tris ex­ec

Last year
Law

Three burn­ing 2024 ques­tions for Pfiz­er: What to do in weight loss, the hunt for megablock­busters, and in­te­grat­ing ...

Last year
Pharma

FDA re­jects mo­tion sick­ness drug from De­fend­er Phar­ma

Last year
Pharma
FDA+

Sen­a­tor turns up heat on in­haler man­u­fac­tur­ers to re­move im­prop­er­ly list­ed Or­ange Book patents

Last year
Pharma
FDA+

Dana­her out­does low fourth-quar­ter rev­enue ex­pec­ta­tions, fore­casts slow 2024

Last year
Financing
Diagnostics

Cre­ative AI gains steam among phar­ma mar­keters in­clud­ing Sanofi, No­var­tis, al­though con­cerns abound

Last year
AI
Pharma

Mar­ket­ingRx roundup: Astel­las menopause drug led NFL TV spend­ing; A pod­cast's deep dive in­to Novo's his­to­ry

Last year
Pharma
Marketing

The aca­d­e­m­ic-en­tre­pre­neur mod­el built com­pa­nies and mint­ed mil­lion­aires. What hap­pens when one of its ear­li­est ...

Last year
People
Startups
First page Previous page 209210211212213214215 Next page Last page
A service from the Financial Times